NeuroOne Medical Technologies Corporation (NMTC)
NASDAQ: NMTC · Real-Time Price · USD
0.8168
-0.0183 (-2.19%)
At close: Oct 28, 2025, 4:00 PM EDT
0.8675
+0.0507 (6.21%)
Pre-market: Oct 29, 2025, 8:28 AM EDT
NMTC Revenue
NeuroOne Medical Technologies had revenue of $1.70M in the quarter ending June 30, 2025, with 105.39% growth. This brings the company's revenue in the last twelve months to $6.63M, up 69.00% year-over-year. In the fiscal year ending September 30, 2024, NeuroOne Medical Technologies had annual revenue of $3.45M with 1.33% growth.
Revenue (ttm)
$6.63M
Revenue Growth
+69.00%
P/S Ratio
4.32
Revenue / Employee
$389,944
Employees
17
Market Cap
40.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 3.45M | 45.37K | 1.33% |
| Sep 30, 2023 | 3.41M | 1.29M | 60.73% |
| Sep 30, 2022 | 2.12M | 1.88M | 772.60% |
| Sep 30, 2021 | 242.96K | -1.68M | -87.39% |
| Sep 30, 2020 | 1.93M | - | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NMTC News
- 21 days ago - NeuroOne Medical Technologies Corporation - Special Call - Seeking Alpha
- 7 weeks ago - NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025 - GlobeNewsWire
- 2 months ago - NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain - GlobeNewsWire
- 2 months ago - NeuroOne Medical Technologies Corporation (NMTC) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9% - GlobeNewsWire
- 3 months ago - NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update - GlobeNewsWire
- 3 months ago - NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - GlobeNewsWire
- 3 months ago - NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office - GlobeNewsWire